Novavax (NASDAQ: NVAX) has had an incredible run over the last year and a half, jumping from $4 a share in January 2020 to a recent price of $200. Is the stock still a buy? What's the long-term future for this vaccine biotech?
Corinne Cardina, bureau chief of healthcare and cannabis for the Motley Fool, and Fool.com writer Taylor Carmichael discuss the future of Novavax stock. This Fool Live clip was recorded on June 18.
Source Fool.com